Who makes LTX-315 consecutive lesions?

LTX-315 consecutive lesions is developed by Lytix Biopharma AS.

What development phase is LTX-315 consecutive lesions in?

LTX-315 consecutive lesions is in Phase 1.

Last reviewed 2026-04-19 · How we verify

LTX-315 consecutive lesions

Lytix Biopharma AS · Phase 1 active Small molecule

At a glance

Generic name	LTX-315 consecutive lesions
Also known as	Protocol version 4
Sponsor	Lytix Biopharma AS
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LTX-315 consecutive lesions CI brief — competitive landscape report
LTX-315 consecutive lesions updates RSS · CI watch RSS
Lytix Biopharma AS portfolio CI